Chinese concept stocks are once again popular! Morgan Stanley has raised the ratings of multiple Chinese concept internet companies, and these industries are highly favored.

①Australia's well-known bank Macquarie released a report, upgrading the ratings of multiple Chinese internet-related stocks; ②The reason for the upgrade is the improved visibility of profits, as well as the continuous policy support from the Chinese government.

cls.cnOct 7 21:06 ET

How to Capitalize on the Ongoing Bull Market for Chinese Stocks

Noah JohnsonOct 1 03:32 ET

CFO Liu Wenjing of China Merchants Cigna: Lowering the benchmark interest rate helps to alleviate the risk of "profit margin loss" in the life insurance industry, and insists on pursuing the global health strategy across the market cycle.

①Over the past decade, the national debt yield has long been lower than the upper limit of the pricing interest rate of insurance products, while the yield on the insurance assets side has been continuously narrowing, leading to a certain interest rate spread risk in the industry. ②Building a global strategy for health, adhering to the path of health, this is the top priority of the current strategic goal of China Merchants Cigna, and also a trump card for China Merchants Cigna to navigate through economic cycles.

cls.cnSep 14 10:01 ET

With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?

According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...

cls.cnSep 9 20:54 ET

Is the chain of pharmacies entering a "mini ice age"? H1 growth rate "downgrades", the industry's high-growth stores may reach turning point.

① The growth rate of sales revenue of all categories in retail pharmacies has slowed down, and the competition in stock continues to intensify. In the first half of this year, it was difficult for major chain pharmacies to increase revenue and profit. ② In the future, the focus of pharmacy competition will shift to commodity extension and services. According to the prediction of Zhongkang Industry Research Institute, the growth rate of pharmaceuticals in all end terminals in 2024 is expected to decrease to 4.9%, a decrease from 2023.

cls.cnSep 2 05:25 ET

Will you be eliminated if you don't go overseas? In the first half of the year, the proportion of innovative drug outbound business development accounted for about 80% | Industry Dynamics.

①At the 2024 New Investment Conference hosted by Frost Sullivan, the issue of going global was favored by participants. ②There is a new trend in the export of innovative drugs in China, for example, the number of export BDs exceeded License-in for the first time in 2023. ③Some participating experts put forward rational opinions and called for internal strength, not just enthusiasm.

cls.cnAug 31 03:06 ET